{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:22:52Z","timestamp":1760217772753},"reference-count":34,"publisher":"Japan Society for Clinical Immunology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn.J.clin.Immun","Jpn. J. Clin. Immunol."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2177\/jsci.39.8","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T22:07:17Z","timestamp":1463177237000},"page":"8-17","source":"Crossref","is-referenced-by-count":3,"title":["Prognosis and progress in immunotherapies for organ involvements in systemic autoimmune diseases"],"prefix":"10.2177","volume":"39","author":[{"given":"Shinsuke","family":"YASUDA","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihito","family":"KONO","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"SHIMAMURA","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"KURITA","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"ODANI","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"ATSUMI","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"972","reference":[{"key":"1","unstructured":"1) Kono, M., et al.: Long-term outcome in Japanese patients with lupus nephritis. <i>Lupus<\/i>. <b>23<\/b>: 1124-1132, 2014."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Steinberg, A.D., Steinberg, S.C.: Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. <i>Arthritis Rheum<\/i>. <b>34<\/b>: 945-950, 1991.","DOI":"10.1002\/art.1780340803"},{"key":"3","unstructured":"3) Houssiau, F.A., et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. <i>Arthritis Rheum<\/i>. <b>46<\/b>: 2121-2131, 2002."},{"key":"4","unstructured":"4) Chan, T.M., et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. <i>N Engl J Med<\/i>. <b>343<\/b>: 1156-1162, 2000."},{"key":"5","unstructured":"5) Ginzler, E.M., et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. <i>N Engl J Med<\/i>. <b>353<\/b>: 2219-2228, 2005."},{"key":"6","unstructured":"6) Isenberg, D., et al. Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study. <i>Rheumatology (Oxford)<\/i>. <b>49<\/b>: 128-140, 2010."},{"key":"7","unstructured":"7) Yasuda, S., et al.: Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan. <i>Modern rheumatology\/the Japan Rheumatism Association<\/i>. <b>25<\/b>: 854-857, 2015."},{"key":"8","unstructured":"8) Miyasaka, N., et al.: Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study. <i>Mod Rheumatol<\/i>. <b>19<\/b>: 606-615, 2009."},{"key":"9","unstructured":"9) Chen, W., et al.: Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. <i>Am J Kid Dis<\/i>. <b>57<\/b>: 235-244, 2011."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Mok, C.C., et al.: Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. <i>Ann Rheum Dis<\/i>. 2014.","DOI":"10.1136\/annrheumdis-2014-206456"},{"key":"11","unstructured":"11) Houssiau, F.A., et al.: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. <i>Ann Rheum Dis<\/i>. <b>69<\/b>: 2083-2089, 2010."},{"key":"12","unstructured":"12) Dooley, M.A., et al.: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. <i>N Engl J Med<\/i>. <b>365<\/b>: 1886-1895, 2011."},{"key":"13","unstructured":"13) Hahn, B.H., et al.: American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care Res<\/i>. <b>64<\/b>: 797-808, 2012."},{"key":"14","unstructured":"14) Condon, M.B., et al.: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. <i>Ann Rheum Dis<\/i>. <b>72<\/b>: 1280-1286, 2013."},{"key":"15","unstructured":"15) Kurita, T., et al.: The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis\/dermatomyositis. <i>Lupus<\/i>. <b>24<\/b>: 3-9, 2015."},{"key":"16","unstructured":"16) Sato, S., et al.: RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. <i>Arthritis Rheum<\/i>. <b>60<\/b>: 2193-2200, 2009."},{"key":"17","unstructured":"17) Nakashima. R., et al.: The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. <i>Rheumatology (Oxford)<\/i>. <b>49<\/b>: 433-440, 2010."},{"key":"18","unstructured":"18) Nagasaka, K., et al.: Efficacy of combination treatment with cyclosporin A and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. <i>Mod Rheumatol<\/i>. <b>13<\/b>: 231-238, 2003."},{"key":"19","unstructured":"19) Oddis, C.V., et al.: Tacrolimus in refractory polymyositis with interstitial lung disease. <i>Lancet<\/i>. <b>353<\/b>: 1762-1763, 1999."},{"key":"20","unstructured":"20) Ochi, S., et al.: Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis. <i>Clinical and experimental rheumatology<\/i>. <b>23<\/b>: 707-710, 2005."},{"key":"21","unstructured":"21) Kurita, T., et al.: The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. <i>Rheumatology (Oxford)<\/i>. <b>54<\/b>: 39-44, 2015."},{"key":"22","unstructured":"22) Kowal-Bielecka, O., et al.: EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). <i>Ann Rheum Dis<\/i>. <b>68<\/b>: 620-628, 2009."},{"key":"23","unstructured":"23) Tashkin, D.P., et al.: Cyclophosphamide versus placebo in scleroderma lung disease. <i>N Engl J Med<\/i>. <b>354<\/b>: 2655-2666, 2006."},{"key":"24","unstructured":"24) Hoyles, R.K., et al.: A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. <i>Arthritis Rheum<\/i>. <b>54<\/b>: 3962-3970, 2006."},{"key":"25","unstructured":"25) Yilmaz, N., et al.: Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. <i>Int J Rheum Dis<\/i>. <b>17<\/b>: 923-928, 2014."},{"key":"26","unstructured":"26) Burt, R.K., et al.: Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. <i>Lancet<\/i>. <b>378<\/b>: 498-506, 2011."},{"key":"27","unstructured":"27) Tsukamoto, H., et al.: A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. <i>Ann Rheum Dis<\/i>. <b>65<\/b>: 508-514, 2006."},{"key":"28","unstructured":"28) Bohgaki, T., et al.: Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression. <i>J Rheumatol<\/i>. <b>36<\/b>: 1240-1248, 2009."},{"key":"29","unstructured":"29) van Laar, J.M., et al.: Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. <i>Jama<\/i>. <b>311<\/b>: 2490-2498, 2014."},{"key":"30","unstructured":"30) Burt, R.K., et al.: Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis. <i>Lancet<\/i>. <b>381<\/b>: 1116-1124, 2013."},{"key":"31","unstructured":"31) Odani, T., et al.: Up-regulated expression of HLA-DRB5 transcripts and high frequency of the HLA-DRB5*01:05 allele in scleroderma patients with interstitial lung disease. <i>Rheumatology (Oxford)<\/i>. <b>51<\/b>: 1765-1774, 2012."},{"key":"32","unstructured":"32) Giuggioli, D., et al.: Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. <i>Autoimmun rev<\/i>. <b>14<\/b>: 1072-1078, 2015."},{"key":"33","unstructured":"33) Moazedi-Fuerst, F.C., et al.: Decrease in autoantibody titres during long-term treatment of scleroderma with rituximab: a promising surveillance marker of therapy? <i>Scand J Rheum<\/i>. <b>44<\/b>: 519-520, 2015."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Franklyn, K., et al.: Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). <i>Ann Rheum Dis<\/i>. 2015.","DOI":"10.1136\/annrheumdis-2015-207726"}],"container-title":["Japanese Journal of Clinical Immunology"],"original-title":["\u5168\u8eab\u6027\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u306e\u81d3\u5668\u5408\u4f75\u75c7\u306e\u4e88\u5f8c\u3068\u514d\u75ab\u6cbb\u7642\u306e\u9032\u6b69"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/1\/39_8\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T17:08:56Z","timestamp":1567876136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jsci\/39\/1\/39_8\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2177\/jsci.39.8","relation":{},"ISSN":["0911-4300","1349-7413"],"issn-type":[{"value":"0911-4300","type":"print"},{"value":"1349-7413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}